Dendrite Creates Integrated Support Center Designed Specifically for the Needs of the Pharmaceutical Industry.

BEDMINSTER, N.J. -- Newly Enhanced Help Desk Services Provide Pharmaceutical Sales Representatives and Home Office Unparalleled, Multi-Channel Support in the Field

Dendrite International, Inc. (NASDAQ: DRTE), a leading provider of sales, marketing, clinical and compliance solutions for the life sciences industry, today announced the launch of its Integrated Support Center, offering industry leading, pharmaceutical-specific sales support services. Unlike a traditional help desk, Dendrite's Integrated Support Center features a Customer Interaction Hub to enable service integration, history tracking and linkage across multiple service channels, and continues to be backed by pharmaceutical industry-dedicated service experts who on average handle over three million calls per year, worldwide.

Dendrite's Integrated Support Center enables problem resolution through its easily accessible channels ranging from Interactive Voice Response (IVR), web self-service, chat and email to phone. With these newly enhanced, integrated features, sales representatives can get the right answers to the simplest or the most complex questions through the right channel.

Dendrite's pharmaceutical industry-trained expert personnel form the critical underpinning of the Integrated Support Center. This enables Dendrite to quickly and effectively resolve issues that range from the simplest password reset and Internet connectivity to the more complex physician call plans, sample management and regulatory compliance.

"Today's pharmaceutical landscape is heavily reliant on new, integrated technologies that enable the sales representative to focus on building relationships with the physicians rather than dealing with administrative tasks," said Dave Escalante, vice president of product management at Dendrite. "Approximately 73 percent of all Dendrite support calls involve process diagnostic issues that require expert human interaction."

Dendrite's Integrated Support Center is backed by decades of pharmaceutical industry experience. Resolving over three million global sales support calls annually for large, mid- and emerging pharmaceutical companies has enabled Dendrite to deliver greater than industry average first call resolution.

"The new capabilities customers can leverage through the Integrated Support Center reflect Dendrite's commitment to creating adaptive and leading-edge solutions designed to improve pharmaceutical sales and marketing productivity," said Joe Ripp, president and COO at Dendrite. "Helping our customers meet their business challenges has been and will continue to be a top priority, and we are confident that the Integrated Support Center will continue to evolve to support the growing needs of the pharmaceutical industry."

About Dendrite

Founded in 1986, Dendrite International (NASDAQ: DRTE) enables sales, marketing, clinical and compliance solutions for the global, pharmaceutical industry. The company has clients in more than 50 countries and includes the world's top 20 pharmaceutical companies. For more information please visit www.dendrite.com.

Note: Dendrite is a registered trademark of Dendrite International, Inc.

This document may contain forward-looking statements that may be identified by such forward-looking terminology as "expect," "believe," "anticipate," "will," "intend," "plan," "target," "outlook," "guidance," and similar statements or variations. Such forward-looking statements are based on our current expectations, estimates, assumptions and projections and involve significant risks and uncertainties, including risks which may result from our dependence on the pharmaceutical industry; fluctuations in quarterly revenues due to lengthy sales and implementation cycles for certain of our solutions; our fixed expenses in relation to fluctuating revenues and variations in customers' budget cycles; dependence on certain major customers; changes in demand for our products and services attributable to any weakness experienced in the economy or mergers, acquisitions and consolidations in the pharmaceutical industry; successful and timely development and introduction of new products and versions; rapid technological changes; increased competition; international operations; integrating the entities we acquire; our ability to effectively manage our growth; the protection of our proprietary technology; our ability to compete in the Internet-related products and services market; the continued demand for Internet-related products and services; the ability of our third party vendors to respond to technological change; our ability to maintain our relationships with third-party vendors; less favorable than anticipated results from strategic relationships; dependence of data solutions on strategic relationships; events which may affect the U.S. and world economies; and catastrophic events which could negatively affect our information technology infrastructure. Other important factors that should be reviewed and carefully considered are included in the company's 10-K, 10-Qs, and other reports filed with the SEC. Actual results may differ materially. The company assumes no obligation for updating any such forward-looking statements to reflect actual results, changes in assumptions or other changes affecting such forward-looking statements.